More Stories

Informist, Saturday, May 30, 2026

--Wockhardt gets US FDA approval for co's antibiotic Zaynich 

MUMBAI – Wockhardt Ltd. has received the US Food and Drug Administration's approval for its injectable antibiotic Zaynich, according to an exchange filing from the company Saturday. Zaynich is used to treat adult patients with complicated urinary tract infections, including pyelonephritis.

The antibiotic targets multiple penicillin-binding proteins simultaneously. "This unique, multi-target synergy provides bactericidal activity against the most challenging drug-resistant Gram-negative bacteria for which there are currently very limited treatment options," the company said.

For the March quarter on a consolidated basis, Wockhardt reported a net profit of INR 1.66 billion on revenues of INR 9.65 billion. Friday, its shares closed at INR 2,031.40 on the National Stock Exchange, up 15% from Wednesday. The stock market was shut Thursday for Id-ul-Zuha (Bakri Id).  End

Reported by Ashutosh Pati

Edited by Rajeev Pai

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2026. All rights reserved.